Bio Plus Co

Bio Plus Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 22.28. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 11.66 — a change of 91.04% (higher).

EV/EBITDA

22.28

YoY

91.04%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Bio Plus Co is 2025 22.28 . EV/EBITDA (Enterprise Value to EBITDA) of Bio Plus Co was 2024 11.66 . It decreases by 91.04% higher compared to the previous year.

The Bio Plus Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
83.06 KRW
Jan 1, 2019
45.10 KRW
Jan 1, 2020
25.13 KRW
Jan 1, 2021
17.01 KRW
Jan 1, 2022
9.89 KRW
Jan 1, 2023
9.44 KRW
Jan 1, 2024
11.66 KRW
Jan 1, 2025
22.28 KRW
The Bio Plus Co EV/EBITDA history
YEAREV/EBITDAYoY
22.28+91.04%
11.66+23.57%
9.44-4.59%
9.89-41.85%
17.01-32.30%
25.13-44.28%
45.10-45.70%
83.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

EV/EBITDA (Enterprise Value to EBITDA) of Bio Plus Co is 22.28 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Bio Plus Co changed from 11.66 to 22.28, representing a 91.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bio Plus Co

All Key Metrics — Bio Plus Co